Table 2.
Concentration of DiR (ng/g tissue) measured within specific CNS regions of the central nervous system (CNS) following intranasal administration of nanoparticles.
| Time | CNS Region | Ctr-NPs1 | RVG-NPs1 | Targeting2 |
|---|---|---|---|---|
| 0.5 h | Brain | |||
| Olfactory Bulb | 627.8 ± 507.6 | 325.7 ± 189.8 | −48% | |
| Cortex | 120.7 ± 95.5 | 95.5 ± 93.3 | −21% | |
| Striatum | 241.8 ±130.9 | 234.4 ± 217.1 | −3% | |
| Midbrain | 260.3 ± 98.4 | 271.2 ± 135.6 | +4% | |
| Hippocampus | 148.5 ± 115.6 | 164.3 ± 127.7 | +11% | |
| Cerebellum | 234.4 ± 78.6 | 223.8 ± 128.1 | −5% | |
| Brain Stem | 205.6 ± 89.5 | 235.7 ± 174.6 | +15% | |
| Spinal Cord3 | ||||
| SC-C | 278.1 ± 98.6 | 263.7 ± 155.3 | −5% | |
| SC-T | 122.1 ± 76.4 | 111.8 ± 77.2 | −8% | |
| SC-L | 85.2 ± 72.4 | 99.2 ± 74.4 | +16% | |
| SC-S | 126.8 ± 107.3 | 121.7 ± 87.7 | −4% | |
| 2 h | Brain | |||
| Olfactory Bulb | 227.8 ± 257.1 | 359.9 ± 244.4 | +58% | |
| Cortex | 73.7 ± 101.4 | 46.3 ± 25.9 | −37% | |
| Striatum* | 43.4 ± 19.4 | 160.4 ± 93.6 | +270% | |
| Midbrain* | 51.2 ± 20.1 | 154.7 ± 108.8 | +202% | |
| Hippocampus | 41.5 ± 21.9 | 87.4 ± 83.6 | +111% | |
| Cerebellum | 68.4 ± 79.6 | 108.9 ± 84.5 | +59% | |
| Brain Stem* | 70.0 ± 40.8 | 186.1 ± 139.7 | +166% | |
| Spinal Cord | ||||
| SC-C | 40.1 ± 35.7 | 114.3 ± 106.3 | +185% | |
| SC-T | 40.7 ± 20.4 | 42.5 ± 12.6 | +5% | |
| SC-L | 38.2 ± 29.1 | 39.0 ± 3.7 | +2% | |
| SC-S | 69.2 ± 107.6 | 29.8 ± 10.0 | −57% | |
| 6 h | Brain | |||
| Olfactory Bulb | 133.5 ± 222.6 | 63.0 ± 27.7 | −53% | |
| Cortex | 33.8 ± 26.9 | 27.6 ± 10.5 | −18% | |
| Striatum | 51.6 ± 40.0 | 38.1 ± 10.5 | −26% | |
| Midbrain | 50.6 ± 37.2 | 39.3 ± 27.8 | −22% | |
| Hippocampus | 41.1 ± 35.3 | 28.2 ± 9.6 | −31% | |
| Cerebellum | 47.3 ± 37.8 | 32.0 ± 11.4 | −32% | |
| Brain Stem | 46.2 ± 26.3 | 51.8 ± 29.7 | +12% | |
| Spinal Cord | ||||
| SC-C | 96.2 ± 74.1 | 70.7 ± 31.8 | −26% | |
| SC-T | 37.6 ± 9.1 | 31.0 ± 10.2 | −18% | |
| SC-L | 30.2 ± 17.4 | 27.8 ± 9.4 | −8% | |
| SC-S | 37.9 ± 8.8 | 43.3 ± 22.5 | +14% | |
1 Mean ± standard deviation for control, non-targeted nanoparticles (ctr-NPs) and Rabies Virus Glycoprotein, targeted nanoparticles (RVG-NPs); n = 5–6 mice per group. 2 Targeting is defined as the percent increase or decrease in RVG relative to biotin; 3 SC = spinal cord, C = cervical, T = thoracic, L = lumbar, and S = sacral. * Delivery from RVG-NPs was statistically significantly greater than delivery from ctr-NPs.